IMC.AX
Price:
$0.082
Market Cap:
$18.79M
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III re...[Read more]
Industry
Biotechnology
IPO Date
1999-04-30
Stock Exchange
ASX
Ticker
IMC.AX
According to Immuron Limited’s latest financial reports and current stock price. The company's current ROE is -45.89%. This represents a change of 167.48% compared to the average of -17.15% of the last 4 quarters.
The mean historical ROE of Immuron Limited over the last ten years is -57.20%. The current -45.89% ROE has changed -19.78% with respect to the historical average. Over the past ten years (40 quarters), IMC.AX's ROE was at its highest in in the June 2009 quarter at 313.44%. The ROE was at its lowest in in the June 2013 quarter at -1420.84%.
Average
-57.20%
Median
-53.22%
Minimum
-143.08%
Maximum
-12.31%
Discovering the peaks and valleys of Immuron Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 182.77%
Maximum Annual ROE = -12.31%
Minimum Annual Increase = -65.52%
Minimum Annual ROE = -143.08%
Year | ROE | Change |
---|---|---|
2024 | -54.58% | 182.77% |
2023 | -19.30% | 56.74% |
2022 | -12.31% | -61.97% |
2021 | -32.38% | -37.57% |
2020 | -51.86% | -18.12% |
2019 | -63.34% | 77.54% |
2018 | -35.68% | -65.52% |
2017 | -103.49% | -27.67% |
2016 | -143.08% | 155.69% |
2015 | -55.96% | 52.21% |
The current ROE of Immuron Limited (IMC.AX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-28.73%
5-year avg
-34.09%
10-year avg
-57.20%
Immuron Limited’s ROE is greater than Imugene Limited (-95.62%), greater than Biotron Limited (-423.05%), greater than Patrys Limited (-83.38%), greater than PharmAust Limited (-86.89%), greater than Invion Limited (-34.85%),
Company | ROE | Market cap |
---|---|---|
-95.62% | $319.85M | |
-423.05% | $15.34M | |
-83.38% | $6.17M | |
-86.89% | $111.93M | |
-34.85% | $18.16M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immuron Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immuron Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Immuron Limited's ROE?
How is the ROE calculated for Immuron Limited (IMC.AX)?
What is the highest ROE for Immuron Limited (IMC.AX)?
What is the 3-year average ROE for Immuron Limited (IMC.AX)?
What is the 5-year average ROE for Immuron Limited (IMC.AX)?
How does the current ROE for Immuron Limited (IMC.AX) compare to its historical average?